Horimoto M, Nishikawa M, Ishihara T, Yoshikawa N, Yoshimura M, Inada M
Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
J Clin Endocrinol Metab. 1995 Apr;80(4):1124-8. doi: 10.1210/jcem.80.4.7714080.
To investigate the cause(s) of central hypothyroidism with normal or elevated TSH concentrations, we evaluated the bioactivity of serum TSH as well as pituitary and thyroid function. Seven hypothyroid patients had documented deficiencies of anterior pituitary hormones other than TSH. Basal TSH concentrations ranged from 2.2-14.8 microU/mL. Six patients had low T4 and free T4 concentrations; the remaining patient had a low free T4 and a low normal T4 level with an elevated TSH concentration of 14.4 microU/mL. The mean increment in TSH 30, 60, and 90 min after TRH administration (mean delta TSH) in these patients was 13.5 +/- 9.1 microU/mL (mean +/- SD), which was not significantly different from the value in controls (9.2 +/- 3.5 microU/mL). However, the ratio of the T3 increment at 120 min (delta T3) to mean delta TSH (delta T3/mean delta TSH) in patients was 53.9 +/- 29.3 ng/microU, significantly lower than the control value of 239.5 +/- 97.5 ng/microU (P < 0.01), suggesting that the thyroid response to endogenous TSH was blunted. The serum T4 concentration correlated with the mean delta TSH in these patients (r = 0.78; P < 0.05), suggesting that hypothyroidism is dependent on conserved pituitary function. The mean bioactivity to immunoreactivity ratio of basal TSH in patients was 0.97 +/- 0.27 and was not significantly different from the normal value of 1.05 +/- 0.22. One of the two patients with high basal TSH (> 10 microU/mL) had a ratio of 0.59, which is just below the mean +/- SD of normal subjects (0.61), suggesting that most patients had normal TSH bioactivity in vitro. Our findings suggest that in vivo bioactivity of TSH is decreased because of a pituitary disorder, but in vitro bioactivity of TSH is variable in patients with central hypothyroidism.
为了探究促甲状腺激素(TSH)浓度正常或升高的中枢性甲状腺功能减退的病因,我们评估了血清TSH的生物活性以及垂体和甲状腺功能。7例甲状腺功能减退患者被记录存在除TSH外的垂体前叶激素缺乏。基础TSH浓度范围为2.2 - 14.8微单位/毫升。6例患者的血清总甲状腺素(T4)和游离T4浓度较低;其余1例患者游离T4低,T4水平略低于正常,TSH浓度升高至14.4微单位/毫升。这些患者在促甲状腺激素释放激素(TRH)给药后30、60和90分钟时TSH的平均增加值(平均△TSH)为13.5±9.1微单位/毫升(平均值±标准差),与对照组的值(9.2±3.5微单位/毫升)无显著差异。然而,患者在120分钟时三碘甲状腺原氨酸的增加值(△T3)与平均△TSH的比值(△T3/平均△TSH)为53.9±29.3纳克/微单位,显著低于对照组的值239.5±97.5纳克/微单位(P < 0.01),提示甲状腺对内源性TSH的反应减弱。这些患者的血清T4浓度与平均△TSH相关(r = 0.78;P < 0.05),提示甲状腺功能减退依赖于垂体功能的保留。患者基础TSH的平均生物活性与免疫反应性比值为0.97±0.27,与正常比值1.05±0.22无显著差异。2例基础TSH升高(> 10微单位/毫升)的患者中,有1例的比值为0.59,略低于正常受试者的平均值±标准差(0.61),提示大多数患者的TSH体外生物活性正常。我们的研究结果表明,由于垂体疾病,TSH的体内生物活性降低,但中枢性甲状腺功能减退患者的TSH体外生物活性存在差异。